Genomic tools are helping to guide the search for new insights into uncommon childhood cancers like pediatric Acute Myeloid Leukemia (AML) and lymphomas — insights that, researchers hope, will improve survival rates and better spare survivors of childhood cancers from long-term treatment-associated health effects in adulthood, according to experts who spoke Saturday, December 5  at the 57th American Society of Hematology (ASH) Annual Meeting.